The FDA has granted traditional approval to Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgA nephropathy at risk of progression.

VIVO explains how ddPCR and NGS support viral surveillance in antiviral trials, from detection and quantification to ...

As Africa’s energy sector enters a new phase of development, market intelligence is playing an increasingly important role in ...

In late June, Lexington firefighters had to be called after water rapidly filled the parking lot and first floor of an ...

Lithium-ion battery fires aboard commercial aircraft have moved from a niche dangerous-goods concern to a broad operational ...

Fox News, MS NOW and CNN are using profitable linear TV businesses to invest in streaming, memberships and digital products.

Xencor's XmAb819 demonstrated a 25% response rate and 70% disease control in heavily pre-treated ccRCC patients. Read why ...

Physical access control systems generate a continuous stream of intelligence-rich data, yet most organizations use it only ...

ICIJ and GIJN collaborated on this guide to help reporters kick-start their investigation or deepen their knowledge of the ...

Actinogen Medical Limited (ASX: ACW) today announces that results from its proof-of-concept trial, entitled “A phase 2 randomised, doub ...

NEW HAVEN, Conn., July 20, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization ...

Adults with type 2 diabetes who took a GLP-1 receptor agonist while maintaining six to eight healthy lifestyle habits ...